Court approves Bayer’s Roundup class settlement
- The Missouri court’s final approval order is subject to appeal.
- Monsanto will make declining, capped annual payments for up to 21 years, totalling up to $7.25 billion, including payments already made.
- The settlement covers people exposed before February 17, 2026, who have NHL or receive a diagnosis within 16 years of the agreement’s effective date.
- An appeal would pause further Monsanto payments until the appeals are resolved.
Settlement approval
A Missouri state court granted final approval to a nationwide class settlement covering current and future claims alleging non-Hodgkin’s lymphoma (NHL) injuries from Roundup™. The approval order is subject to appeal. The agreement contains no admission of liability or wrongdoing.
Funding and eligibility
Monsanto will fund the settlement through declining, capped annual payments for up to 21 years, totalling up to $7.25 billion, inclusive of payments already made. The settlement covers people who allege exposure to Roundup™ before February 17, 2026, and have an NHL diagnosis or receive one within 16 years after the agreement’s effective date.
Appeals and remaining claims
An appeal of the approval order would pause further Monsanto payments until the appeals are exhausted. Bayer expects opt-outs to represent a very low percentage of current and potential future claims and says it is adequately provisioned for the remaining litigation.
Source: Bayer